Journal of Clinical Endocrinology & Metabolism, Vol 81, 3535-3539, Copyright © 1996 by Endocrine Society

ARTICLES

A preliminary study of flutamide, testolactone, and reduced hydrocortisone dose in the treatment of congenital adrenal hyperplasia

L Laue, DP Merke, JV Jones, KM Barnes, S Hill and GB Cutler Jr
Developmental Endocrinology Branch, National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland 20892, USA.

Treatment outcome in congenital adrenal hyperplasia is often suboptimal due to hyperandrogenism, treatment-induced hypercortisolism, or both. As a new approach, we hypothesized that the effects of androgen could be blocked by an antiandrogen (flutamide) and an inhibitor androgen to estrogen conversion (testolactone), thus allowing the hydrocortisone dose to be reduced. We conducted a short term pilot study in 12 children with congenital adrenal hyperplasia in a randomised cross-over open design to determine whether flutamide, testolactone, reduced hydrocortisone dose, and fludrocortisone are more effective than hydrocortisone and fludrocortisone treatment in normalizing linear growth, weight gain, and bone maturation. Each regimen was administered for 6 months, with a 3-month washout period, consisting of hydrocortisone and fludrocortisone treatment, between regimens. Compared to hydrocortisone and fludrocortisone treatment, the regimen of flutamide, testolactone, reduced hydrocortisone dose (from 12.9 to 7.9 mg/m2 day), and fludrocortisone produced an increase in plasma 17- hydroxyprogesterone levels (P < 0.05) and a decline in urinary cortisol (P < 0.01), linear growth rate (-0.9 +/- 0.5 vs. 1.4 +/- 0.6 SD U; P = 0.003), weight velocity (-0.80 +/- 4.0 vs 0.6 +/- 0.4 SD U; P = 0.01), and bone maturation (0.6 +/- 0.6 vs. 1.4 +/- 0.9 yr bone age/yr chronological age; P = 0.02). Although no important adverse effects were observed, the known potential for flutamide-induced hepatotoxicity made frequent monitoring essential. We conclude that the regimen of flutamide, testolactone, reduced hydrocortisone does, and fludrocortisone improve the short term control of growth and bone maturation in children with congenital adrenal hyperplasia. Long term studies are required to determine whether this approach can improve these children's growth and development.

This article has been cited by other articles:

				W. Bonfig, S. B. Dalla Pozza, H. Schmidt, P. Pagel, D. Knorr, and H. P. Schwarz Hydrocortisone Dosing during Puberty in Patients with Classical Congenital Adrenal Hyperplasia: An Evidence-Based Recommendation J. Clin. Endocrinol. Metab., October 1, 2009; 94(10): 3882 - 3888. [Abstract] [Full Text] [PDF]

				W. Bonfig, S. Bechtold, H. Schmidt, D. Knorr, and H. P. Schwarz Reduced Final Height Outcome in Congenital Adrenal Hyperplasia under Prednisone Treatment: Deceleration of Growth Velocity during Puberty J. Clin. Endocrinol. Metab., May 1, 2007; 92(5): 1635 - 1639. [Abstract] [Full Text] [PDF]

				G. Pinto, V. Tardy, C. Trivin, C. Thalassinos, S. Lortat-Jacob, C. Nihoul-Fekete, Y. Morel, and R. Brauner Follow-Up of 68 Children with Congenital Adrenal Hyperplasia due to 21-Hydroxylase Deficiency: Relevance of Genotype for Management J. Clin. Endocrinol. Metab., June 1, 2003; 88(6): 2624 - 2633. [Abstract] [Full Text] [PDF]

				E. Charmandari, K. A. Calis, M. F. Keil, M. R. Mohassel, A. Remaley, and D. P. Merke Flutamide Decreases Cortisol Clearance in Patients with Congenital Adrenal Hyperplasia J. Clin. Endocrinol. Metab., July 1, 2002; 87(7): 3197 - 3200. [Abstract] [Full Text] [PDF]

				D. P. Merke, S. R. Bornstein, N. A. Avila, and G. P. Chrousos Future Directions in the Study and Management of Congenital Adrenal Hyperplasia due to 21-Hydroxylase Deficiency Ann Intern Med, February 19, 2002; 136(4): 320 - 334. [Abstract] [Full Text] [PDF]

				P. F. Collett-Solberg Congenital Adrenal Hyperplasia: From Genetics and Biochemistry to Clinical Practice, Part 2 Clinical Pediatrics, March 1, 2001; 40(3): 125 - 132. [Abstract] [PDF]

				Section on Endocrinology and Committee on Genetics Technical Report: Congenital Adrenal Hyperplasia Pediatrics, December 1, 2000; 106(6): 1511 - 1518. [Abstract] [Full Text]

				P. C. White and P. W. Speiser Congenital Adrenal Hyperplasia due to 21-Hydroxylase Deficiency Endocr. Rev., June 1, 2000; 21(3): 245 - 291. [Abstract] [Full Text]

				D. P. Merke, M. F. Keil, J. V. Jones, J. Fields, S. Hill, and G. B. Cutler Jr. Flutamide, Testolactone, and Reduced Hydrocortisone Dose Maintain Normal Growth Velocity and Bone Maturation Despite Elevated Androgen Levels in Children with Congenital Adrenal Hyperplasia J. Clin. Endocrinol. Metab., March 1, 2000; 85(3): 1114 - 1120. [Abstract] [Full Text]

				T. C. Lee, W. L. Miller, and R. J. Auchus Medroxyprogesterone Acetate and Dexamethasone Are Competitive Inhibitors of Different Human Steroidogenic Enzymes J. Clin. Endocrinol. Metab., June 1, 1999; 84(6): 2104 - 2110. [Abstract] [Full Text]

				E. A. Cummings, S. R. Salisbury, M. L. Givner, and R. S. Rittmaster Testolactone-Associated High Androgen Levels, a Pharmacologic Effect or a Laboratory Artifact? J. Clin. Endocrinol. Metab., March 1, 1998; 83(3): 784 - 787. [Abstract] [Full Text]

				D. P. Merke and G. B. Cutler Jr New Approaches to the Treatment of Congenital Adrenal Hyperplasia JAMA, April 2, 1997; 277(13): 1073 - 1076. [Abstract] [PDF]